Wahler, Steffen; Müller, Alfred; Fuchs, Sabine; von … - In: Health Economics Review 12 (2022) 1, pp. 1-14
Introduction: Until recently, adjuvant treatment options for higher stage resectable cutaneous melanoma were limited. Two studies with a similar set-up, published 2017, led to registration of targeted therapy for BRAF-mutated melanoma with dabrafenib and trametinib as well as of the...